Drug intelligence / Profile preview

AST-011

Development stage: Preclinical
Lead developer: Astrogen
Modality: Small Molecules

Overview

AST-011 is a preclinical-stage drug candidate developed by Astrogen, a biotechnology company based in South Korea. It is identified as a second-generation treatment for Autism Spectrum Disorder (ASD), following the company's lead asset, AST-001. The program is currently in the discovery and early preclinical phase, aimed at addressing the core symptoms of neurodevelopmental disorders. While the specific molecular target has not been publicly detailed, the drug is part of a pipeline focused on modulating neurological pathways to treat conditions with high unmet medical needs.

Beyond the preview

Go deeper on AST-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AST-011.

Explore the full profile